OUR SCIENCE
A New Paradigm for T cell Therapies
Tmod™ cells uniquely differentiate tumor from normal cells
Our proprietary Tmod™ platform is designed to overcome barriers in current cancer treatment.
Current cell therapies work by binding to and killing tumor cells that overexpress “tumor-associated” antigens. However, most of these antigens are not truly tumor-specific and are also expressed on normal cells. Thus, most cancer therapies are ultimately limited by unacceptable toxicities to normal and healthy tissues.
Safeguarding normal cells increases the therapeutic window to access unexploited targets & reduces constraints caused by toxicity.
Tmod™ Platform
Integrating multiple signals to deliver exquisite selectivity
Blocker
Recognizes antigens on normal cells that protect them from destruction
Activator
Recognizes antigens on tumor cells that trigger their killing
Our proprietary Tmod™ platform is a robust, portable system that accommodates a broad range of activator(s) and blocker combinations. New product candidates can be generated with each new combination of activator(s) and blocker(s), opening up the potential to achieve unprecedented selectivity and specificity in cell targeting.
Tmod™ Platform
A2 Bio’s unique Tmod™ platform is a robust, portable system that accommodates a broad range of activator and blocker combinations where each activator/blocker combination represents a new product candidate. The platform can be applied to both autologous and allogeneic immune cell therapies for many tumor types.
Enabling precise and personalized
T cell therapies
Powerful Applications
Solid Tumor Cancers
Our approach takes advantage of damage inside tumor cells, called Loss of Heterozygosity (LOH). LOH refers to irreversible genetic losses that are a common event in tumor progression and highly specific to tumor cells.
The activator and blocker on the Tmod™ T cell are designed to signal based on the presence and absence of antigens displayed on the cell surface. The activator recognizes antigens which are present on both tumor and normal cells, and binds to initiate killing. On the normal cell, however, the blocker recognizes the antigen expressed by the presence of both alleles (no LOH) and turns off the activator’s killing, sparing the normal cells.
Other Indications
Solid tumor cancer therapy is one of many potential applications of this technology. Tmod™ can be applied to other indications where target and non-target cells have differential antigen expressions, for example, hematological cancers as well as autoimmune diseases.